Decreased CT-number in the pancreatic parenchyma is a reliable imaging biomarker of the presence of malignancies in patients with high-risk intraductal papillary mucinous neoplasm.

Aged Biomarkers Carcinoma, Intraductal, Noninfiltrating / diagnostic imaging Cohort Studies Female Humans Male Middle Aged Pancreas / diagnostic imaging Pancreatectomy Pancreatic Function Tests Pancreatic Juice / cytology Pancreatic Neoplasms / diagnostic imaging Predictive Value of Tests Prognosis Spleen / diagnostic imaging Tomography, X-Ray Computed

CT number of pancreas IPMN Pancreatic cancer Pancreatic steatosis

Journal

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

ISSN: 1424-3911

Titre abrégé: Pancreatology

Pays: Switzerland

ID NLM: 100966936

Informations de publication

Date de publication:
Apr 2020

Historique:

received: 27 09 2019

revised: 29 01 2020

accepted: 18 02 2020

pubmed: 9 3 2020

medline: 27 2 2021

entrez: 9 3 2020

Statut: ppublish

Résumé

Intraductal papillary mucinous neoplasm (IPMN) is a premalignant cystic neoplasm of the pancreas and is frequently detected in imaging investigations. A proportion of the patients with IPMN develop malignancies including high-grade dysplasia and invasive carcinoma. To predict the presence of malignancies in IPMN, constant imaging follow-up is usually required. Pancreatic steatosis (PS) has been recently identified as a facilitating factor for pancreatic cancer, and can be predicted through computed tomography (CT). We hypothesized that the CT-number of the pancreatic parenchyma could be a new reliable imaging biomarker for IPMN patients. Eighty-six patients undergoing pancreatectomy for IPMN were investigated. Using preoperative CT, the pancreatic index (PI) was calculated by dividing the CT-number of the pancreas by that of the spleen. Malignancies were pathologically detected in 63 cases (73.3%). Patients were divided into two cohorts according to the presence of malignancies and were compared for various factors including the PI scores. The comparison of the two cohorts detected significant differences in two parameters (CA19-9 and PI score), and the PI score was the most sensitive biomarker to predict the presence of malignancies in patients showing high-risk stigmata of IPMN. Pancreatic CT-number is an additional reliable imaging biomarker in distinguishing patients with IPMN having malignancies when investigating the patients showing high-risk stigmata.

Sections du résumé

BACKGROUND BACKGROUND

METHODS METHODS

Eighty-six patients undergoing pancreatectomy for IPMN were investigated. Using preoperative CT, the pancreatic index (PI) was calculated by dividing the CT-number of the pancreas by that of the spleen.

RESULTS RESULTS

Malignancies were pathologically detected in 63 cases (73.3%). Patients were divided into two cohorts according to the presence of malignancies and were compared for various factors including the PI scores. The comparison of the two cohorts detected significant differences in two parameters (CA19-9 and PI score), and the PI score was the most sensitive biomarker to predict the presence of malignancies in patients showing high-risk stigmata of IPMN.

CONCLUSIONS CONCLUSIONS

Pancreatic CT-number is an additional reliable imaging biomarker in distinguishing patients with IPMN having malignancies when investigating the patients showing high-risk stigmata.

Identifiants

DOI: 10.1016/j.pan.2020.02.014 PMID: 32146046

pubmed: 32146046

pii: S1424-3903(20)30050-8

doi: 10.1016/j.pan.2020.02.014

pii:

doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

442-447